We are co-investigators and a site for the HTA funded COmBinging memantine And cholinesterase inhibitors in Lewy body dementia treatment Trial (COBALT). This started recruitment earlier this year and is a multi-site study randomised controlled trial in the UK and Australia which will examine the effectiveness of memantine (compared to placebo) as a pharmacological treatment for those living with dementia with Lewy bodies or Parkinson’s disease dementia. The trial lasts for one year with the primary outcome at 6 months and includes a number of outcomes including such as cognition, daily functioning, neuropsychiatric symptoms, motor function, health economics and global outcome.